RxDoctor Payments Data

May Kim, MD

Family Medicine · Flower Mound, TXNPI 1386844744

Payments from drug & device makers

$1,407in general payments, 2019–2025

Across 66 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • Amgen$203
  • Merz North America, Inc.$141
  • Pfizer$128
  • Exact Sciences$126
  • Lilly USA, LLC$99
  • plus $477 from 13 others

What the payments were for

  • Food & beverage$1,407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,407 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,400
Medicare patients
116
Services billed
1,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$76,518
JardianceEmpagliflozin26$42,028
ProliaDenosumab15$26,534
TrulicityDulaglutide11$20,079
CreonLipase/Protease/Amylase15$12,362
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,092
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$2,800
Atorvastatin Calcium390$2,714
ProgesteroneProgesterone, Micronized52$2,401
Metformin Hcl198$1,421
Boostrix TdapDiphth,pertuss(Acell),tet Vac20$1,275
Memantine Hcl32$1,201
Amlodipine Besylate139$1,105
Levothyroxine Sodium114$975
Ibandronate Sodium24$953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$76,51856 claims
Boehringer IngelheimJardiance$21$42,02826 claims
AmgenProlia$203$26,53415 claims
Lilly USA, LLCTrulicity$99$20,07911 claims
AbbVieCreon$234$12,36215 claims
GSKShingrix$74$4,09219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Flower Mound

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →